An old drug candidate, from the 1980s, can help new clinical trials find the right patient category for new cancer drugs. That was the conclusion of a researcher couple at Sahlgrenska Cancer Center, University of Gothenburg, Sweden. By digging through the medical literature they re-discovered a forgotten drug molecule.

The findings are described in the article ”Cancer differentiation agent hexamethylene bisacetamide was likely the first BET bromodomain inhibitor in clinical trials” (Nilsson LM et al), published in Cancer Research in March 2016: http://www.ncbi.nlm.nih.gov/pubmed/26...